Show simple item record

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

dc.contributor.authorStewart, GD
dc.contributor.authorAitchison, M
dc.contributor.authorBex, A
dc.contributor.authorLarkin, J
dc.contributor.authorLawless, C
dc.contributor.authorMéjean, A
dc.contributor.authorNathan, P
dc.contributor.authorOades, G
dc.contributor.authorPatard, J-J
dc.contributor.authorPaul, J
dc.contributor.authorRavaud, A
dc.contributor.authorEscudier, B
dc.contributor.authorRenal Cross Channel Group
dc.date.accessioned2017-04-13T09:45:11Z
dc.date.issued2017-06
dc.identifier.citationEuropean urology, 2017, 71 (6), pp. 845 - 847
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/588
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2016.10.029
dc.description.abstractDespite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
dc.formatPrint-Electronic
dc.format.extent845 - 847
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectRenal Cross Channel Group
dc.subjectHumans
dc.subjectCarcinoma, Renal Cell
dc.subjectKidney Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectProtein Kinase Inhibitors
dc.subjectTreatment Outcome
dc.subjectChemotherapy, Adjuvant
dc.subjectNephrectomy
dc.subjectEvidence-Based Medicine
dc.subjectRandomized Controlled Trials as Topic
dc.subjectMolecular Targeted Therapy
dc.subjectCytoreduction Surgical Procedures
dc.titleCytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
dc.typeJournal Article
dcterms.dateAccepted2016-10-14
rioxxterms.versionofrecord10.1016/j.eururo.2016.10.029
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue6
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume71
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, James
dc.contributor.icrauthorMarsden,


Files in this item

Thumbnail
Name:
JL2_CNx reflection paper European ...
Size:
196.4Kb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record